Partnering has always been key to the success of Adenosine Therapeutics,
from its founding in 1999 to today. With the reacquisition of Stedivaze, Adenosine Therapeutics now possesses
a unique partnering opportunity: a late Phase III drug program in a proven, growing market of more than
Clinical trial data to date suggest that Stedivaze® has the potential to demonstrate equivalent efficacy,
compared to the standard of care, as well as best-in-class product attributes.
Two Phase III trials are 70% and 24% complete. Resumption and
completion should be relatively straightforward and fast.
Stedivaze has a strong patent estate with a long life.
Adenosine Therapeutics is actively seeking a partner to help us bring this important and valuable drug to market.
Interested parties are invited to contact us.
Invitees may visit our Virtual Data Room.